Ratings Novavax, Inc.

Equities

NVAX

US6700024010

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
4.47 ^USD	0.00%		-5.10%	-6.88%

May. 07	Shah Capital Launches Campaign Urging Stockholders to Vote Against the Re-Election of Novavax?s Directors	CI
May. 06	Novavax's Shareholder Shah Capital Urges Vote Against Re-Election of Directors	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.13 for the 2024 fiscal year.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
NOVAVAX, INC.	-6.88%	623M	C-
MODERNA, INC.	+23.37%	46.71B	B-
LONZA GROUP AG	+48.83%	41.8B	A
IQVIA HOLDINGS INC.	-0.94%	41.52B	B
CELLTRION, INC.	-5.86%	29.55B	C
ICON PUBLIC LIMITED COMPANY	+11.29%	25.78B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.92%	19.26B	B
BIO-TECHNE CORPORATION	+3.20%	12.14B	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	12.08B	C+
MEDPACE HOLDINGS, INC.	+30.23%	11.98B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes